organization · Reporting owner
ProQuest Investments IV, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EAGLE PHARMACEUTICALS, INC.
Report date May 15, 2017 · Filed May 15, 2017
Jointly reported with ProQuest Financial LLC, ProQuest Associates IV LLC, Moorin Jay, SCHREIBER ALAIN
Section 16 reporting ended · disclosed 2017-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy ProQuest Investments IV, L.P. | 0 |
Reported balance
After 2017-05-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-05-15 · Other · Disposed 3,584,087 · Balance 0 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. F1: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy Jay Moorin directly and through IRA | 172,381 |
Reported balance
After 2017-05-15 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-05-15 · Other · Acquired 149,107 · Balance 172,381 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy Alain Schreiber | 149,107 |
Reported balance
After 2017-05-15 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-05-15 · Other · Acquired 149,107 · Balance 149,107 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy ProQuest Financial LLC | 6,777 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,777 F2: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
F2: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration.
UroGen Pharma Ltd.
Report date November 27, 2017 · Filed November 29, 2017
Jointly reported with ProQuest Associates IV LLC, Moorin Jay, SCHREIBER ALAIN
Section 16 reporting ended · disclosed 2017-11-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per shareSEC Table I · non-derivative | Direct | 1,242,031 |
Last balance in matching sequence
After 2017-11-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-11-27 · Sale · Disposed 31,491 · Balance 1,419,838 F2: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Row 2 · 2017-11-28 · Sale · Disposed 177,807 · Balance 1,242,031 F3: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares.
F2: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
F3: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2017 Filed Nov 29, 2017 17:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares, par value NIS 0.01 per share | 177,807 | $40.51 | $7,202,961.57 |
DisclosureSEC source: 0000932440-17-000088 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,242,031 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.direct: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares, par value NIS 0.01 per share | 31,491 | $41.12 | $1,294,909.92 |
DisclosureSEC source: 0000932440-17-000088 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419,838 F2 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.direct: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Read SEC document |
| May 15, 2017 Filed May 15, 2017 08:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | OtherCommon Stock $0.001 par value | 149,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000932440-17-000039 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alain Schreiber Disclosed balance after: 149,107 F3 · shares: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. Read SEC document |
| May 15, 2017 Filed May 15, 2017 08:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | OtherCommon Stock $0.001 par value | 149,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000932440-17-000039 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin directly and through IRA Disclosed balance after: 172,381 F3 · shares: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. Read SEC document |
| May 15, 2017 Filed May 15, 2017 08:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | OtherCommon Stock $0.001 par value | 3,584,087 | $0.00 | $0.00 |
DisclosureSEC source: 0000932440-17-000039 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 0 F3 · shares: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 22 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 20,000 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $46.09 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 21 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 10,000 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 9,360 | $0.00 Strike: $12.67 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 20 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 9,360 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 3,120 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 19 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 3,120 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 2,340 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 18 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 2,340 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 2,340 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 17 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 2,340 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 2,340 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 16 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 2,340 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 2,340 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 15 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 2,340 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (right to buy) · Derivative | 2,340 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · derivative · entry 14 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 0 Underlying: Common Stock $0.001 par value · 2,340 shares Expires 2017-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 2,961 | $89.09 | $263,795.49 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 12 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 6,777 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $89.00 to $89.23. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 51,219 | $88.34 | $4,524,686.46 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 11 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 9,738 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $88.00 to $88.99. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 20,000 | $59.31 | $1,186,200.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 10 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 60,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 10,000 | $46.09 | $460,900.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 9 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 40,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 9,360 | $12.67 | $118,591.20 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 8 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 30,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 3,120 | $4.42 | $13,790.40 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 7 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 21,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 2,340 | $8.78 | $20,545.20 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 6 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 18,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 2,340 | $8.78 | $20,545.20 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 16,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 2,340 | $8.78 | $20,545.20 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 13,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 2,340 | $4.04 | $9,453.60 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 11,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 16:19 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock $0.001 par value | 2,340 | $0.90 | $2,106.00 |
DisclosureSEC source: 0000932440-17-000034 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 9,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 17:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 61,420 | $83.13 | $5,105,844.60 |
DisclosureSEC source: 0000932440-17-000032 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,584,087 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.51. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 17:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 23,689 | $83.02 | $1,966,660.78 |
DisclosureSEC source: 0000932440-17-000032 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,645,507 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.42. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 17:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 6,223 | $83.00 | $516,509.00 |
DisclosureSEC source: 0000932440-17-000032 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,669,196 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.03. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 29, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,600 | $83.01 | $132,816.00 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 7 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 23,274 Read SEC document |
| March 29, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 500 | $83.01 | $41,505.00 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 6,777 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 29, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 58,755 | $83.01 | $4,877,252.55 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,675,419 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.11. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 28, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 6,182 | $83.02 | $513,229.64 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,734,174 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.13. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,300 | $83.00 | $107,900.00 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 6 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 24,874 Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 400 | $83.00 | $33,200.00 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 7,277 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 17:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 37,731 | $83.00 | $3,131,673.00 |
DisclosureSEC source: 0000932440-17-000030 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,740,356 F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 23, 2017 Filed Mar 23, 2017 17:02 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 700 | $83.01 | $58,107.00 |
DisclosureSEC source: 0000932440-17-000020 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,778,087 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.07. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 21, 2017 Filed Mar 23, 2017 17:02 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 500 | $83.10 | $41,550.00 |
DisclosureSEC source: 0000932440-17-000020 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,778,787 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $83.00 to $83.49. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 20, 2017 Filed Mar 20, 2017 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 51,883 | $82.10 | $4,259,594.30 |
DisclosureSEC source: 0000932440-17-000018 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,779,287 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $82.00 to $82.55. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0,001 par value | 38,997 | $82.01 | $3,198,143.97 |
DisclosureSEC source: 0000932440-17-000018 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,831,170 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $82.00 to $82.10. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 9,120 | $82.08 | $748,569.60 |
DisclosureSEC source: 0000932440-17-000018 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,870,167 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $82.00 to $82.45. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 16:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 65,114 | $85.16 | $5,545,108.24 |
DisclosureSEC source: 0000932440-17-000002 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,879,287 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $85.00 to $85.92. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 15,551 | $85.00 | $1,321,835.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 7 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,944,401 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $85.00 to $85.10. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,300 | $85.00 | $110,500.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 6 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 26,174 Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 300 | $85.00 | $25,500.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 7,677 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,700 | $87.05 | $147,985.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,959,952 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $87.03 to $87.09. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 100 | $86.06 | $8,606.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,961,652 F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 167 | $86.00 | $14,362.00 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,961,752 F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 17:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 15,368 | $85.10 | $1,307,816.80 |
DisclosureSEC source: 0000932440-16-000526 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,961,919 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $85.00 to $85.82. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 102,919 | $80.09 | $8,242,782.71 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 7 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 3,977,287 F10 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $80.00 to $80.82. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 19,581 | $79.24 | $1,551,598.44 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 6 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,080,206 F9 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $79.00 to $79.90. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.